Thursday, 12 December 2019

Neuropathology Market in depth study and analysis published, 2019

Market Synopsis of the Global Neuropathology Market
Neuropathology pertains to the aliment of nerves reculting in pain and numbness of the limbs and it is gaining prominence in this market. The increasing incidence of musculoskeletal conditions and technological advancements in medical diagnostic devices are some factors responsible for the growth of the global neuropathology market.
The number of patients suffering from cerebrovascular disorders has increased rapidly and has reached an all-time high in the past few years. There has been a significant rise in the number of surgeries associated with the treatment of such disorders. As the neurosurgeries and spinal surgeries are very critical, continuous monitoring during the whole procedure proves to be beneficial as the information about the electrical signals in brain and the nerves can be obtained in real time.
The Global market of Neuropathology is expected to grow at a CAGR of approximately 6% during the forecast period 2019-2023.
Biopsies primarily consist of the skin. The recently developed neuropathy test, the epidermal nerve fiber density testing (ENFD) in which the nerve fibers of the skin is analysed by performing a  punch skin biopsy to identify small fiber neuropathies. This pathology test is becoming available in selected labs as well as a few universities; it replaces the traditional sural nerve biopsy test and is less invasive. It is used to identify painful small fiber neuropathies.
According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases. Many healthcare professionals have started using these diagnostics techniques, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for Neuropathology.
Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
  • ARUP Laboratories
  • Therapath LLC
  • Abbott Laboratories
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd.
  • Sakura Finetek USA Inc.
  • Danaher Corporation
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.N
  • NeoGenomics Laboratories
Segmentation
The Neuropathology is segmented on the basis of diagnosis test, application, and end-users.
On the basis of diagnostic test, the market is segmented into the biopsy, body fluids, peripheral blood smears, tissue resections, and others 
The biopsy sub-segment is divided into Epidermal nerve fiber density testing (ENFD), Sural nerve biopsy test, bone-marrow biopsies, lymph-node biopsies and others
On the basis of product, the application market is segmented into cerebral hypoxia and stroke, perinatal disorders, CNS infections, demyelinative diseases, brain tumors, neurodegenerative diseases, inherited metabolic disorders, peripheral neuropathy, and myopathology
On the basis of end-user, the market is segmented into hospitals, clinics, research centers and others.
Regional Analysis
The Global Neuropathology Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global neuropathology market owing to the increasing healthcare expenditure in North America since 2016. U.S. has some of the best hospitals in the world with state of the art infrastructure. Most of the hospitals and their neurology departments are well equipped with the equipment that is required for the working of the neuropathology techniques. Various organizations and private companies are engaged in the activities of spreading awareness about the benefits of the neuropathology test among common people through various educational and marketing ways. As a result, huge numbers of people are opting for the neuropathology tests as a point of care. The country has been developing number of academic courses to develop skilled personnel in the neuropathology field over the years. Hence the availability of the neuropathology specialists in North American countries is high.
Europe is the second largest market for neuropathology market. For Europe, the neuropathology market including the brain tumors market is regarded as a strong competitive market. European countries are now making efforts in promoting the benefits of the intraoperative neurophysiological monitoring services. Patient friendly healthcare and insurance policies are making a positive impact on the people taking medical assistance.
Asia Pacific is the fastest growing region over the forecast period. The healthcare spending in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Browse Complete 100 Pages Premium Research Report Enabled with 62 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/neuropathology-market-4978  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Urethritis Market 2019–By Identifying the Key Market Segments and Key players holding market share

Urethritis is an inflammation of the urethra, or the tube that carries urine. It shows various symptoms such as pain while urinating and an increased urge to urinate. Additionally, burning sensation while urinating, presence of blood in the semen or urine, frequent urge and discomfort while urinating, abnormal discharge from the vagina or penis, etc. are other common symptoms. Other serious manifestation of urethritis include damage to the reproductive system, pelvic inflammatory disease (PID), which can result in infertility, and others. The primary cause of urethritis is usually infection by bacteria, while viral infection for pre-existing sexually transmitted diseases being the secondary cause. Urethritis is also caused by mechanical or chemical damage to the urethra during treatment or catheterization. Urethritis should not be confused with urinary tract infection (UTI). Urethritis is an inflammation of the urethra, while a UTI is an infection of the urinary tract and both may have similar symptoms, but often require different treatment.
Females have a greater chance of developing urethritis than males because of the nearness of urethra to the anus, which increases the chance of microbial infection. Also men’s urethras is much longer than women’s. According to the Centers for Disease Control and Prevention (CDC), causative organisms associated with urethritis include Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Human papillomavirus (HPV),  Herpes simplex virus (HSV), and Cytomegalovirus (CMV) and others. According to Antimicrobe, Nongonococcal bacteria caused urethritis in approximately 4 million Americans in 2015 accounting for 80% of the cases. According to Department of Health, U.K., urethritis accounts for 0.005% of hospital consulting with a high 97% of hospital consulting for urethritis requiring hospital admission. Almost 20% of hospital admissions for urethritis requires an emergency.
Rising demand for the treatment due to growing population, increasing screening, rising number of geriatrics, rising safety and success of drug treatment, the extricating nature of the pain, and others are driving the growth of the market. However, complications of treatment such as side effects, emergence of bacterial resistance to antibiotics, cost of urethritis treatment, and others may hamper the market growth.
Key Players in the Global Urethritis Market
  • Hoffmann-La Roche AG,
  • GlaxoSmithKline,
  • AbbVie,
  • Johnson & Johnson, and Merck & Co.,
  • Eli Lilly and Company,
  • Bristol-Myers Squibb Company,
  • Bayer AG,
  • AstraZeneca plc. and others.
Segments
The global urethritis market has been segmented on the basis of types, diagnosis, drug treatment, and end user.
Based on the types, the market has been segmented as infective urethritis and nonspecific urethritis.
Based on the diagnosis, the market has been segmented as physical examination, microbial culture tests, and others.
Based on the drug treatment, the market has been segmented as pain killers, anti-bacterials, antivirals, and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.
Global Urethritis Market Regional Analysis
The Americas accounts for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of hospitalization procedures due to greater healthcare penetration in the U.S. and Canada drives the urethritis market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates are adding fuel to the market growth. The consolidation of large healthcare players in the U.S. also leads the growth of the market due to increased  buying power of the healthcare players.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future urethritis market in the region.
Europe is the second largest market in the world due to growing healthcare industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to the large pharmaceutical industry.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/urethritis-market-4795
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Diastematomyelia Market to show steady growth, 2019

Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.
A number of diagnostic procedures are available in the market for the diagnosis of the diastematomyelia. Increasing healthcare expenditure and rising government support have supported the growth of the market. According to the Boston Children's Hospital, in 2015, 5% of children across the globe were suffering from sustain spinal cord injuries. Furthermore, rapid development in the imaging technology and continuous improvement in the medical services have fuelled the market growth. The cost associated with the surgeries is very high which is not affordable for the people in developing region. Thus, high cost of surgeries, and lack of the precise treatment may restrain the growth of the market.
 The Global Diastematomyelia Market is expected to grow at a CAGR of 8.3% during forecast period 2017-2023.
Key players
The major key players in the global diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)
SegmentationThe global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.
On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).
On the basis of host, the market is segmented into children and adults.
On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.
Regional Analysis
Asia Pacific is the fastest growing region in the global diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.
The Americas dominates the global diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.
Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.
Whereas, the Middle East & Africa owns the least share of the global diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/diastematomyelia-market-4794
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Viral Gastroenteritis Market 2019 - Opportunity, Driving Trends and deep study 2023

Market Synopsis of the Global Viral Gastroenteritis Market
Viral Gastroenteritis is one of the common gastrointestinal disease across the globe. It is a communicable disease transmitted through contaminated food or water and direct contact with the infected person. Notovirus is the common cause of viral gastritis in various developed and developing countries across the globe. Viral Gastroenteritis Market Information By Type of Virus (Norovirus, Rotavirus), By Diagnosis (Physical Examination, Rapid Stool Test), By Drugs (Antibiotics, Antacids, Laxatives, Antimotility Agents), By Indication (Watery Diarrhea, Vomiting) and By End Use (Hospitals, Clinics, Diagnostic Centers, others) - Global Forecast till 2023
Rising prevalence of Gastrointestinal Disease across the globe, demand for new drugs for the treatment and increasing expenses on research and development in gastroenterology fuel the market growth. Additionally, the growing concerns about the spread of the disease among children and an urgent need to manage viral gastroenteritis also contribute to the market growth.
Fierce competition among key market players acts as a barrier for the new entrant in the market.
The global viral gastroenteritis market is expected to grow at a CAGR of 7.5% during the forecast period.
Bacterial resistance to commonly used antibiotics such as penicillin and amoxicillin may be the leading restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrant in the market.
According to the World Health Organization (WHO), diarrheal diseases are a major cause of hospitalizations and child deaths globally.
Segmentation
The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.
On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.
On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.
On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.
On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.
On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.
Regional Analysis   
In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostic tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will propel the growth of the Asia Pacific market.
America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center For Disease Control And Prevention (CDC), each year on average in the United States, there are 19 to 21 million cases of acute gastroenteritis.
Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.
The Middle East & Africa also show a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection.

Key Players 
  • Valeant Pharmaceuticals International Inc. (U.S.),
  • Janssen Global Services, LLC (U.S.),
  • Takeda Pharmaceutical (Japan),
  • Bayer AG (Germany),
  • Sanofi (France),
  • Allergan (Ireland),
  • GlaxoSmithKline (U.S.),
  • Abbott (U.S.),  
  • AstraZeneca (U.K).
Browse Complete 206 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/viral-gastroenteritis-market-4438
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Enema Based Products Market - Granular Market Report and Review, 2019

Market Synopsis of the Global Enema Based Products Market
The global enema based products market is expected to show sharp growth over the forecast period. Rising prevalence of gastrointestinal disorders such as constipation across the globe, availability of various types of enema administration kits such as cleansing and carminative enema and overall demand for enema administration products drivers the market growth.
Enema based products are used to remove waste for the rectum and can be used at home as a remedial measure for constipation and other gastrointestinal disorders. Constipation is a major gastrointestinal condition, found to be prevalent across the globe. Other condition that may require enema administration are obesity, diabetes, and cancer.
Risk involved in the use of enema based product is irritation in the rectum and embolism, in case of incorrect use of enema administration
According to the latest 2016 data from the World Health Organization, an estimated 422 million adults were living with diabetes mellitus across the globe.
The global enema based products market is expected to grow at a CAGR of 10.2% during the forecast period.
Key Players
Some of the key players in this market are Baxter International, Inc. (U.S), MacoPharma (U.K),  Hollister Incorporated  (U.S), Coloplast Group (Germany), Medline Industries, Inc. (U.S), and B Braun Melsungen AG (Germany).
Segments 
The global enema based products market is segmented on the basis of administration type, indication, preparation, and end users.
On the basis of administration type, market is segmented into cleansing enema, carminative enema, retention enema, return-flow enema, and others. Cleansing enema is further segmented into large volume enema, small volume enema, and prepackaged disposable enema. Retention enema is further segmented into oil enema, sedative enema, nutrient enema, anesthetic enema, medicinal enema, and others.
On the basis of indication, the market is market is segmented into constipation, diarrhea, obesity, cancer and others.
On the basis of preparation, the market is divided into sodium phosphate enemas, coffee enemas, barium enemas, water-soluble contrast enemas and others.  Barium enemas is further segmented into single-column barium enema and double-contrast barium enema.
On the basis of end user, the market is divided into hospitals or clinics, home, and others. 
Avail the in-depth table of content TOC & market synopsis on “enema based products market research report–Global forecast till 2023.” @ https://www.marketresearchfuture.com/reports/enema-based-products-market-4370  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Pediatric Brain Tumor Market 2019 - Opportunity, Driving Trends and deep study 2023

Key Players for Global Pediatric Brain Tumor Market:
Some of the key players in this market are: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others
Pediatric brain tumor is uncontrolled or abnormal growth of normal cell in the brain in children. Brain tumors mainly are of two types, cancerous (malignant) and noncancerous (benign). It is second most common type of cancer in children and it comprise about 25% of childhood cancer.
The cases of pediatric tumors are increasing globally that leading the growth of the market. Advanced diagnostic technology and new treatments are also major driving forces of the market. Rising healthcare infrastructure, extended insurance cover, government initiatives, and emerging economies are driving the market. Rising funding for R&D and clinical trials as well as FDA approvals are also major growth factors for global pediatric brain tumor market.
Segmentation:
Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, non-neuroepithelial tissue tumors, meningeal tumors, and others. Gliomas is further sub-segmented into astrocytoma, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.
On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, Llmbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Angiogram, and others. Magnetic Resonance Imaging (MRI) scan is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic resonance perfusion, Functional MRI (fMRI), and others. Brain or spinal cord tumor biopsy is further sub-segmented into Stereotactic needle biopsy, Craniotomy, and other.
On the basis of treatment, the market has been segmented into surgery, therapies, drug treatment, and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), Shunt placement/revision, and others. Therapies includes Radiation therapy, Chemotherapy, Targeted therapy, and others. Chemotherapy includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, and others. Drug treatment is further sub-segmented into Corticosteroids, Anti-seizure drugs (anti-epileptics), Hormones, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Browse Complete 76 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pediatric-brain-tumor-market-3690
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Carcinoid Syndrome Management Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/carcinoid-syndrome-management-market-2843
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)